213 related articles for article (PubMed ID: 31754924)
21. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
Whittles LK; Didelot X; White PJ
Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
[TBL] [Abstract][Full Text] [Related]
23. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
24. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.
Ultsch B; Damm O; Beutels P; Bilcke J; Brüggenjürgen B; Gerber-Grote A; Greiner W; Hanquet G; Hutubessy R; Jit M; Knol M; von Kries R; Kuhlmann A; Levy-Bruhl D; Perleth M; Postma M; Salo H; Siebert U; Wasem J; Wichmann O
Pharmacoeconomics; 2016 Mar; 34(3):227-44. PubMed ID: 26477039
[TBL] [Abstract][Full Text] [Related]
25. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.
Martinón-Torres F; Taha MK; Knuf M; Abbing-Karahagopian V; Pellegrini M; Bekkat-Berkani R; Abitbol V
Pathog Glob Health; 2022 Mar; 116(2):85-98. PubMed ID: 34569453
[TBL] [Abstract][Full Text] [Related]
26. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
Burman C; Alderfer J; Snow VT
J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
[TBL] [Abstract][Full Text] [Related]
27. Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.
Bousema JC; Ruitenberg J
Int J Health Policy Manag; 2015 Sep; 4(11):757-61. PubMed ID: 26673336
[TBL] [Abstract][Full Text] [Related]
28. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ
PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448
[TBL] [Abstract][Full Text] [Related]
29. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
[TBL] [Abstract][Full Text] [Related]
30. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
[TBL] [Abstract][Full Text] [Related]
32. Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies.
Ruedin HJ; Ess S; Zimmermann HP; Szucs T
Vaccine; 2003 Oct; 21(27-30):4145-52. PubMed ID: 14505894
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
34. Potential public health impact of a
Huang L; Snedecor SJ; Balmer P; Srivastava A
Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
[TBL] [Abstract][Full Text] [Related]
35. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis.
Scott RD; Meltzer MI; Erickson LJ; De Wals P; Rosenstein NE
Am J Prev Med; 2002 Aug; 23(2):98-105. PubMed ID: 12121797
[TBL] [Abstract][Full Text] [Related]
36. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
37. 4CMenB vaccine and its role in preventing transmission and inducing herd immunity.
McMillan M; Marshall HS; Richmond P
Expert Rev Vaccines; 2022 Jan; 21(1):103-114. PubMed ID: 34747302
[TBL] [Abstract][Full Text] [Related]
38. Global practices of meningococcal vaccine use and impact on invasive disease.
Ali A; Jafri RZ; Messonnier N; Tevi-Benissan C; Durrheim D; Eskola J; Fermon F; Klugman KP; Ramsay M; Sow S; Zhujun S; Bhutta Z; Abramson J
Pathog Glob Health; 2014 Jan; 108(1):11-20. PubMed ID: 24548156
[TBL] [Abstract][Full Text] [Related]
39. The missing link: family physician perspectives on barriers and enablers to prescribing a new Meningococcal B vaccine and other recommended, non-government funded vaccines.
Taylor KA; Stocks N; Marshall HS
Vaccine; 2014 Jul; 32(33):4214-9. PubMed ID: 24923639
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study.
Arifin SMN; Zimmer C; Trotter C; Colombini A; Sidikou F; LaForce FM; Cohen T; Yaesoubi R
Med Decis Making; 2019 Jul; 39(5):553-567. PubMed ID: 31268405
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
